Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.41 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.41 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25209429 | 0.94 | KDM4E (0.53) | KDM4EGAAKMT2AABL1FFAR4 | |
| SCHEMBL25240945 | 0.80 | ABL1 (0.47) | KDM4EABL1FFAR4FFAR1SCN9A | |
| SCHEMBL14968582 | 0.80 | SCN9A (0.53) | GAAABL1SCN9ABRAFIGF2BP2 | |
| SCHEMBL1697975 | 0.79 | IGF2BP2 (0.50) | ABL1FFAR4FFAR1PIM1IGF2BP2 | |
| SCHEMBL25211630 | 0.78 | GAA (0.52) | KDM4EGAAKMT2APIM1IGF2BP2 | |
| SCHEMBL25213511 | 0.78 | ALDH1A1 (0.57) | KDM4EGAAKMT2AABL1FFAR4 | |
| SCHEMBL1795070 | 0.77 | ALDH1A1 (0.44) | ABL1FFAR4FFAR1PIM1SCN9A | |
| SCHEMBL30468358 | 0.77 | CHEK1 (0.47) | KDM4EGAAKMT2AABL1FFAR4 | |
| SCHEMBL13407882 | 0.77 | CHEK1 (0.47) | KDM4EGAAKMT2AABL1FFAR4 | |
| SCHEMBL25213585 | 0.76 | CA1 (0.54) | KDM4EGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034122-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2025-01-30 | — | — | US | disclosed |
| EP-4441044-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| CN-118302422-A | Substituted N-cyanopyrrolidines having activity as USP30 inhibitors | 特殊治疗有限公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2023099561-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034122-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | USP30, USP47, USP1 | KDM4E 1010/4885GAA 3398/4885KMT2A 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.